Oncology

Latest News

Patients in the cemiplimab group had superior disease-free survival vs placebo. | Image credit: Medical Works - stock.adobe.com
Cemiplimab Improves Disease-Free Survival in High-Risk, Advanced CSCC

June 13th 2025

Cemiplimab improved disease-free survival in patients with high-risk cutaneous squamous cell carcinoma (CSCC) and performed well in patients with advanced CSCC in the real-world setting.

The approval covers use of pembrolizumab as a single agent in the neoadjuvant setting, followed by adjuvant treatment with pembrolizumab in combination with radiotherapy with or without cisplatin after surgery, and then continued as a single agent. | Image credit: wladimir1804-stock.adobe.com
FDA Approves Perioperative Pembrolizumab in Resectable HNSCC

June 13th 2025

FDA approval-Olivier Le Moal-stock.adobe.com.jpeg
Mitomycin Intravesical Solution Gains FDA Approval for Recurrent Low-Grade NMIBC

June 12th 2025

AJMC
Utilization and Costs Among Oncologists Participating in a Private Insurance Shared Savings Model

June 11th 2025

The new report suggests the C5a-C5aRq axis might be a useful target in combination with existing therapies for cutaneous squamous cell carcinoma. | Image credit: vladimircaribb - stock.adobe.com
C5aR1 Flagged as Biomarker in Cutaneous Squamous Cell Carcinoma

June 7th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

Site Logo
January 28th 2020

American Oncology Network, LLC, Names Todd Schonherz President and Chief Operating Officer

Schonherz will be responsible for day-to-day operations.
CMS Agrees to Cover NGS for Medicare Patients With Breast, Ovarian, Other Cancers
January 28th 2020

CMS Agrees to Cover NGS for Medicare Patients With Breast, Ovarian, Other Cancers

Allison Inserro Mary Caffrey
CMS said it is expanding coverage of next generation sequencing (NGS) for use as a diagnostic for patients with germline breast and ovarian cancer, paving the way for Medicare beneficiaries to receive more personalized medicine. However, an advocate said the wording of CMS' decision could actually limit testing access for some women with breast or ovarian cancer.
Site Logo
January 21st 2020

Bundled Payments: Looking Back, Looking Ahead

Alyssa Dahl, MPH
Jennifer Atkins Explains How Blue Cross Blue Shield Evaluates Emerging Innovations in Cancer Care
January 17th 2020

Jennifer Atkins Explains How Blue Cross Blue Shield Evaluates Emerging Innovations in Cancer Care

Blue Cross Blue Shield utilizes data to drive insights into what works and what doesn't work in cancer care, as well as, delineating trends through our collaboration with provider specialties and organizations across the US, said Jennifer Atkins, MBA, vice president of Network Solutions at Blue Cross Blue Shield.
When Less Is More: Halving Chemo Keeps Testicular Cancer at Bay, Study Finds
January 4th 2020

When Less Is More: Halving Chemo Keeps Testicular Cancer at Bay, Study Finds

Mary Caffrey
Testicular cancer is the most common cancer to be diagnosed in men as younger men—those younger than age 40—and it can be particularly aggressive. Advances in therapy have improved survival rates, but if young men have chemotherapy after surgery, they may live with side effects for decades.
What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer
January 2nd 2020

What We're Reading: Healthcare Issues to Watch; e-Cig Flavor Ban; Google AI and Breast Cancer

AJMC Staff
Five issues in healthcare were spotlighted as key developments to watch; FDA to ban all e-cig vape flavors except for menthol and tobacco; Google AI system shown to improve detection of breast cancer through mammograms.
An Immune-Suppressing Target for Glioblastoma?
December 27th 2019

An Immune-Suppressing Target for Glioblastoma?

Mary Caffrey
A team at The University of Texas MD Anderson Cancer Center in Houston led by original pioneers in immuno-oncology have published a paper in Nature Medicine that discusses an immune-suppressing enzyme that was strongly present in glioblastoma but not in 5 other tumor types the team studied.
Site Logo
December 19th 2019

Improving Survival in Lung Cancer: Commitment of The Lung Ambition Alliance

Giorgio Scagliotti, MD, PhD
For more than 45 years, the International Association for the Study of Lung Cancer has been working tirelessly toward a world without lung and other thoracic cancers. To add strength to our efforts we recently joined with other leading organizations in the lung cancer space to create a powerful force for change: The Lung Ambition Alliance
Future of BCC and CSCC Therapy
December 19th 2019

Future of BCC and CSCC Therapy

Second-Line Systemic Treatment of BCC
December 19th 2019

Second-Line Systemic Treatment of BCC

Systemic Therapy in BCC
December 19th 2019

Systemic Therapy in BCC

Electing for Surgery in the Management of BCC
December 19th 2019

Electing for Surgery in the Management of BCC

Overview of Basal Cell Carcinoma
December 19th 2019

Overview of Basal Cell Carcinoma

Toxicity Profile and Pseudoprogression
December 19th 2019

Toxicity Profile and Pseudoprogression

PD-1 and Other Systemic Treatment Options for CSCC
December 19th 2019

PD-1 and Other Systemic Treatment Options for CSCC

Using Immunotherapy in CSCC
December 19th 2019

Using Immunotherapy in CSCC

Systemic Treatment of CSCC
December 19th 2019

Systemic Treatment of CSCC

Standard of Care for CSCC
December 19th 2019

Standard of Care for CSCC

Overview of Cutaneous Squamous Cell Carcinoma
December 19th 2019

Overview of Cutaneous Squamous Cell Carcinoma

Site Logo
December 18th 2019

Radiation Oncologist Discusses Concerns With Incoming CMS Payment Model

Allison Inserro
As CMS prepares to move forward with new models of value-based cancer care, a radiation oncologist, speaking at the Institute for Value-Based Medicine®, discussed her findings regarding whether accountable care models had an effect on cancer care spending.
Site Logo
December 18th 2019

Hope and Some Skepticism Whether Oncology Payment Models Will Work

Allison Inserro
Coverage from the Institute for Value-Based Medicine® session held in Nashville, Tennessee.
Risk of Heart Failure Greater in Patients With AML, ALL on Anthracyclines
December 18th 2019

Risk of Heart Failure Greater in Patients With AML, ALL on Anthracyclines

Maggie L. Shaw
In cases of acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL), there is a greater risk of symptomatic heart failure in the first year following initiation of anthracycline treatment.
Government-Insured Patients With Breast Cancer Face a Higher Risk of Death
December 17th 2019

Government-Insured Patients With Breast Cancer Face a Higher Risk of Death

Gianna Melillo
Patients with breast cancer who have government insurance face a higher risk of death, according to a retrospective study presented at the 2019 San Antonio Breast Cancer Symposium on December 13.
Site Logo
December 17th 2019

From the Editor-in-Chief: Lead, Follow, or Get Out of the Way

Joseph Alvarnas, MD
Dr Alvarnas is editor-in-chief of Evidence-Based Oncology.™ He is vice president of Government Affairs, senior medical director for Employer Strategy, and associate clinical professor, Hematology & Hematologic Cell Transplantation, City of Hope, Duarte, Califonia.
Site Logo
December 16th 2019

Provider Perspective: Stephen M. Schleicher, MD, MBA, Addresses Accountability Versus Control in Oncology Care First

Mary Caffrey
An article Schleicher co-wrote in JAMA Oncology, which appeared the day before the announcement of Oncology Care First, offered insights into the need for changes to the original OCM.
Site Logo
December 16th 2019

Provider Perspective: Kashyap Patel, MD, Sees Collaboration Going Into Oncology Care First

Mary Caffrey
Kashyap Patel, MD, the chief executive officer of Carolina Blood and Cancer Care Associates—a leading OCM practice—and associate editor of Evidence-Based Oncology™ (EBO), said he’s optimistic about Oncology Care First.
Site Logo
December 16th 2019

Can Cancer Care Lead the Way Toward a Value-Based Future?

Keely Macmillan, MPH
A senior vice president of Archway Health discusses challenges and opportunities of the proposed Oncology Care First model.
Anthracycline, Radiation Treatment for Childhood Cancer Shown to Increase Risk of Adult Breast Cancer
December 12th 2019

Anthracycline, Radiation Treatment for Childhood Cancer Shown to Increase Risk of Adult Breast Cancer

Maggie L. Shaw
There was a 37% increase in childhood cancer survival between 1975 and 2010. With more children receiving chemotherapy and radiation to treat their diseases, leading to more survivors, awareness has grown of the belated effects of those treatments once patients reach adulthood.
Site Logo
December 11th 2019

Outcome Measures for Oncology Alternative Payment Models: Practical Considerations and Recommendations

Jakub P. Hlávka, PhD Pei-Jung Lin, PhD Peter J. Neumann, ScD
This review presents a set of evidence-based outcome measures for oncology alternative payment models, drawing on evidence from existing and proposed quality measures.
Supplemental MRI of Very Dense Breast Tissue Finds Early Cancers, at Higher Risk of False Positives
December 11th 2019

Supplemental MRI of Very Dense Breast Tissue Finds Early Cancers, at Higher Risk of False Positives

Gianna Melillo
A recent study published in The New England Journal of Medicine says that women with dense breast tissue who undergo supplemental magnetic resonance imaging (MRI) tests have lower rates of interval cancers than those who receive only mammography tests, although they also had higher rates of false positive tests.
<1
...
202122232425262728
...
186>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo